HomeCompareNTEC vs GBDC

NTEC vs GBDC: Dividend Comparison 2026

NTEC yields 20.77% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.77M in total portfolio value· pulled ahead in Year 2
10 years
NTEC
NTEC
● Live price
20.77%
Share price
$9.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$7,308.86
Full NTEC calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — NTEC vs GBDC

📍 GBDC pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTECGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTEC + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTEC pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTEC
Annual income on $10K today (after 15% tax)
$1,765.32/yr
After 10yr DRIP, annual income (after tax)
$6,212.53/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,976,911.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTEC + GBDC for your $10,000?

NTEC: 50%GBDC: 50%
100% GBDC50/50100% NTEC
Portfolio after 10yr
$10.46M
Annual income
$8,229,021.35/yr
Blended yield
78.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

NTEC
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTEC buys
0
GBDC buys
0
No recent congressional trades found for NTEC or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTECGBDC
Forward yield20.77%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$76.5K$20.85M
Annual income after 10y$7,308.86$16,450,733.83
Total dividends collected$44.4K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: NTEC vs GBDC ($10,000, DRIP)

YearNTEC PortfolioNTEC Income/yrGBDC PortfolioGBDC Income/yrGap
1$12,777$2,076.84$12,492$1,791.70+$285.00NTEC
2← crossover$16,151$2,479.95$16,527$3,160.58$376.00GBDC
3$20,212$2,929.82$23,588$5,904.90$3.4KGBDC
4$25,053$3,426.51$37,141$11,901.65$12.1KGBDC
5$30,776$3,969.42$66,205$26,463.38$35.4KGBDC
6$37,488$4,557.19$137,452$66,612.65$100.0KGBDC
7$45,300$5,187.86$342,372$195,298.53$297.1KGBDC
8$54,329$5,858.83$1,053,292$686,954.33$999.0KGBDC
9$64,699$6,567.01$4,111,439$2,984,416.95$4.05MGBDC
10$76,537$7,308.86$20,849,974$16,450,733.83$20.77MGBDC

NTEC vs GBDC: Complete Analysis 2026

NTECStock

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Full NTEC Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this NTEC vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTEC vs SCHDNTEC vs JEPINTEC vs ONTEC vs KONTEC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.